Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Anuhya, Kommalapati"'
Autor:
Anuhya Kommalapati, Tawee Tanvetyanon
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 1, Pp 51-54 (2021)
Immunotherapy with a checkpoint inhibitor has revolutionized the treatment of advanced non-small cell lung cancer. Replacing cytotoxic chemotherapy in some settings, immunotherapy with checkpoint inhibitors enables many patients to live longer with m
Externí odkaz:
https://doaj.org/article/b44674857436444c80a99d35a970ba27
Publikováno v:
Biomedicines, Vol 10, Iss 6, p 1304 (2022)
Hepatocellular carcinoma (HCC) is an aggressive malignancy accounting for 90% of primary liver malignancies. Therapeutic options for HCC are primarily based on the baseline functional status, the extent of disease at presentation and the underlying l
Externí odkaz:
https://doaj.org/article/01d37e03df3b4e7e8082804a66f2d1c6
Autor:
Aakash P, Desai, Caleb J, Scheckel, Leah C, Soderberg, Chelsee J, Jensen, Jacob J, Orme, Sri H, Tella, Anuhya, Kommalapati, Joshua C, Pritchett, Nandita, Khera, Amit, Mahipal, Ronald S, Go
Publikováno v:
JCO Oncology Practice. 18:e1247-e1254
PURPOSE: Precision oncology promises improved outcomes but the cost-effectiveness and accessibility of targeted therapies is debatable. We report price change patterns from 2015 to 2019 for several oral anticancer medications for common solid tumor m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d69943c2553d56c6fd6577b53d75bd45
https://doi.org/10.1200/op.21.00847
https://doi.org/10.1200/op.21.00847
Potential Role of Metabolic Intervention in the Management of Advanced Differentiated Thyroid Cancer
Publikováno v:
Frontiers in Oncology, Vol 7 (2017)
Well-differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy that has an excellent prognosis with a 5-year survival rate of about 98%. However, approximately 50% of the patients with DTC who present with distant metastases (adv
Externí odkaz:
https://doaj.org/article/55d81c1a86a34396877b7e4813e1c658
Autor:
Brent J. Small, Anuhya Kommalapati, Aasha I. Hoogland, Heather S.L. Jim, Nathaly Irizarry-Arroyo, Amy K. Otto, Maija Reblin, Michael D. Jain, Anna Barata, Margaret Booth-Jones, Taylor L. Welniak, Aaron Collier, Jennifer M. Logue, Reena Jayani, Frederick L. Locke, Yvelise Rodriguez, Kelly A. Hyland
Publikováno v:
Psychooncology
OBJECTIVE: Informal family caregivers provide critical support for patients receiving chimeric antigen receptor (CAR) T-cell therapy. However, caregivers' experiences are largely unstudied. This study examined quality of life (QOL; physical functioni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb297c371ce72dd1724028e211ecabe6
https://doi.org/10.1002/pon.5674
https://doi.org/10.1002/pon.5674
Autor:
Aaron Mansfield, Anuhya Kommalapati
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(15)
Summary The activity of KRAS inhibitors against brain metastases is relatively unexplored. The recent work on preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial support the potential of adagrasib (MRTX849) to p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bb05c1e269a8bc523b1819f6b988510
https://pubmed.ncbi.nlm.nih.gov/35404402
https://pubmed.ncbi.nlm.nih.gov/35404402
Autor:
Haris Hatic, Shealeigh Inselman, Jonathan Inselman, Anuhya Kommalapati, Sri Harsha Tella, Jonas Paludo, Urshila Durani, Ronald S. Go, Gaurav Goyal
Publikováno v:
Leukemia research. 123
Multiple myeloma (MM) is an incurable plasma cell neoplasm. In this study, we aimed to analyze the impact of time to initiation of systemic therapy for MM on overall survival (OS).We identified cases diagnosed with MM from the National Cancer Databas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b763029cf0af582d9df1bca1e0dbaa0b
https://pubmed.ncbi.nlm.nih.gov/36270091
https://pubmed.ncbi.nlm.nih.gov/36270091
Autor:
Anuhya Kommalapati, Julio C. Chavez, Marco L. Davila, Abu-Sayeef Mirza, Christina A Bachmeier, Frederick L. Locke, Hamza Hashmi, Javier Pinilla-Ibarz, Hien D. Liu, Franco Garcia, Rahul Mhaskar, Constantine Logothetis, Aleksandr Lazaryan, Michael D. Jain, Farhad Khimani, Taiga Nishihori, Bijal D. Shah, Alicia Darwin
Publikováno v:
Blood Adv
Key Points VTE developed in 11% of lymphoma patients after CAR T-cell therapy and was managed safely with anticoagulation. Coagulation abnormalities after CAR T-cell therapy occur but do not commonly lead to bleeding events.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a777bfdfc60afaad8468ad2783e3ac2
https://doi.org/10.1182/bloodadvances.2020002060
https://doi.org/10.1182/bloodadvances.2020002060
Publikováno v:
Cancer Management and Research. 12:51-57
Gastric cancer is the sixth most common cancer and is known to be the fifth-leading cause of cancer-related deaths globally in 2018. Systemic therapy remains the only curative option in advanced gastric carcinoma with the primary goal of improving th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a44b3194ba7e6f4ed92bf845873dcf9d
https://doi.org/10.2147/cmar.s199827
https://doi.org/10.2147/cmar.s199827
Autor:
Aakash Desai, Aaron Scott Mansfield, Anuhya Kommalapati, Konstantinos Leventakos, Alex A. Adjei, Howard Jack West
Publikováno v:
Journal of Clinical Oncology. 40:125-125
125 Background: The advent of immunotherapy (IO) has led to significant improvement in outcomes for patients (pts) with advanced non-small cell lung cancer (adv NSCLC). The rate of crossovers and receipt of post-protocol IO in pivotal trials leading
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2086967b87c614af7a82f08d23af493f
https://doi.org/10.1200/jco.2022.40.28_suppl.125
https://doi.org/10.1200/jco.2022.40.28_suppl.125